The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal Cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer CollaborationFitzmauriceCAllenCGlobal, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of Disease StudyJAMA Oncol20173452454827918777
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• ShapiroJvan LanschotJJBHulshofMNeoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross): long-term results of a randomised controlled trialLancet Oncol20151691090109826254683
   PubMed Web of Science ®Google Scholar
• SjoquistKMBurmeisterBHSmithersBMSurvival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisLancet Oncol201112768169221684205
   PubMed Web of Science ®Google Scholar
• CooperJSGuoMDHerskovicAChemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy Oncology GroupJAMA1999281171623162710235156
   PubMed Web of Science ®Google Scholar
• LagergrenJLagergrenPRecent developments in esophageal adenocarcinomaCA Cancer J Clin201363423224823818335
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin201868173029313949
   PubMed Web of Science ®Google Scholar
• Ter VeerEHaj MohammadNvan ValkenhoefGThe efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysisJ Natl Cancer Inst201610810djw166
   Google Scholar
• AndoNKatoHIgakiHA randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)Ann Surg Oncol2012191687421879261
   PubMed Web of Science ®Google Scholar
• HoningJSmitJKMuijsCTA comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patientsAnn Oncol201425363864324492674
   PubMed Web of Science ®Google Scholar
• SunXHanSGuFA retrospective comparison of taxane and Fluorouracil-based chemoradiotherapy in patients with inoperable esophageal squamous cell carcinomaJ Cancer2016791066107327326249
   PubMed Web of Science ®Google Scholar
• HuGWangZWangYComparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patientsDrug Des Devel Ther20161021292136
   PubMed Web of Science ®Google Scholar
• YamashitaKKatadaNMoriyaHNeoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (dcf NAc) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysisGen Thorac Cardiovasc Surg201664420921526868531
   PubMed Web of Science ®Google Scholar
• OjimaTNakamoriMNakamuraMNeoadjuvant chemotherapy with Divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagusAnticancer Res201636282983426851048
   PubMed Web of Science ®Google Scholar
• ZhangPXiMLiQQConcurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysisOncotarget2016728446864469427183916
   PubMedGoogle Scholar
• YangJ-SWangTQiuM-QLiQ-LComparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancerIntern Med J201545775776125851492
   PubMed Web of Science ®Google Scholar
• NomuraMOzeIAbeTImpact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysisCancer Chemother Pharmacol201576235736326092324
   PubMed Web of Science ®Google Scholar
• UiTFujiiHHosoyaYComparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagusDis Esophagus201528218018724529073
   PubMed Web of Science ®Google Scholar
• ZhaoTChenHZhangTDocetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical studyMed Oncol20122953017302322476809
   PubMed Web of Science ®Google Scholar
• SimH-WChanBANatoriAComparison of chemoradiotherapy (crt) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancerJ Clinl Oncol20173515_suppl4053
   Web of Science ®Google Scholar
• HaisleyKHartKNabavizadehNNeoadjuvant cisplatin/5-FU improves pathologic complete response and survival compared to carboplatin/paclitaxel in esophageal cancerDis Esophagus20162938A
   Google Scholar
• ThomayAASuSFriedantAJFreedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancerJ Clin Oncol2014323_suppl126
   Web of Science ®Google Scholar
• FangMSongTLiangXComparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinomaOncotarget2017823370803709028415745
   PubMedGoogle Scholar
• ZemanovaMPetruzelkaLPazdroAProspective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-upDis Esophagus201023216016719515190
   PubMed Web of Science ®Google Scholar
• AdelsteinDJRiceTWRybickiLADoes paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapyJ Clin Oncol200018102032203910811667
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials2007811617555582
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• BlomRLSosefMNNapMComparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinomaDis Esophagus201427438038724006852
   PubMed Web of Science ®Google Scholar
• Courrech StaalEFAlemanBMvan VelthuysenMLChemoradiation for esophageal cancer: institutional experience with three different regimensAm J Clin Oncol201134434334920562589
   PubMed Web of Science ®Google Scholar
• RoofKSCoenJLynchTJConcurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancerInt J Radiat Oncol Biol Phys20066541120112816730135
   PubMed Web of Science ®Google Scholar
• HsuFMLinCCLeeJMImproved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized studyJ Surg Oncol2008981344118449912
   PubMed Web of Science ®Google Scholar
• BaderFGLordickFFinkUPaclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-upOnkologie200831736637218596383
   PubMedGoogle Scholar
• ChenSZChenXMDingYWangXCZhangFMoKLTherapeutic effect of combined cisplatin and docetaxel vs fluorouracil regimen with concurrent radiotherapy on advanced esophageal carcinomaNan Fang Yi Ke Da Xue Xue Bao2011314727729 Chinese21515482
   PubMedGoogle Scholar
• BaiMWangBWangXMaHWangYWangZRandomized trial of weekly docetaxel and cisplatin combined with concurrent 3DCRT in patients with locally advanced esophageal cancerChin Ger J Clin Oncol2013128361364
   Google Scholar
• KushidaTNoharaSYoshinoKUtility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysisDis Esophagus201427436837323865505
   PubMed Web of Science ®Google Scholar
• KatadaNYamashitaKKatadaCNeoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU (dcf) in esophageal squamous cell carcinoma and its short-term prognosisEsophagus2014113173181
   Web of Science ®Google Scholar
• WangJYuYZhanB-HGeNZhouQRadiotherapy concurrent with paclitaxel plus cisplatin vs 5-fluorouracil plus cisplatin for esophageal cancerWorld Chin J Digestol201523243904
   Google Scholar
• BoggsDHTarabolousCMorrisCGAnalysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancerDis Esophagus201528761962524863682
   PubMed Web of Science ®Google Scholar
• WuSChenMYLuoJCWeiLChenZComparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinomaZhonghua Zhong Liu Za Zhi20123411873876 Chinese23291141
   PubMedGoogle Scholar
• AkiyamaYIwayaTEndoFInvestigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinomaSurg Endosc201832139139928664431
   PubMed Web of Science ®Google Scholar
• SchellenbergDPeixotoRLeeALimHJA province-wide retrospective comparison of pathologic response and progression-free survival in locally advanced esophagus cancer patients treated with either cisplatin-5FU (CF) or carboplatin-paclitaxel (CP) concurrent with radiation (XRT) with or without surgeryJ Clin Oncol2014323_suppl10724323033
   PubMed Web of Science ®Google Scholar
• BermanATBarskyARMickRPerioperative complications after neoadjuvant chemoradiation for locally advanced esophageal cancer: a comparison of platinum/5-FU (PF) and carboplatin/paclitaxel (Pt)Int J Radiat Oncol Biol Phys2014901S205
   Web of Science ®Google Scholar
• ChenYZhaoKYeJSafety results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1)J Clin Oncol20173515_suppl406629095681
   PubMed Web of Science ®Google Scholar
• MuroKHamaguchiTOhtsuAA phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnn Oncol200415695595915151954
   PubMed Web of Science ®Google Scholar
• AlbertssonMJohanssonBFrieslandSPhase II studies on docetaxel alone every third week, or Weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancerMed Oncol200724440741217917090
   PubMed Web of Science ®Google Scholar
• AjaniJAIlsonDHDaughertyKPazdurRLynchPMKelsenDPActivity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagusJ Natl Cancer Inst19948614108610917912736
   PubMedGoogle Scholar
• IlsonDHWadleighRGLeichmanLPKelsenDPPaclitaxel given by a Weekly 1-H infusion in advanced esophageal cancerAnn Oncol200718589890217351256
   PubMed Web of Science ®Google Scholar
• NordmannAJKasendaBBrielMMeta-analyses: what they can and cannot doSwiss Med Wkly2012142w1351822407741
   PubMed Web of Science ®Google Scholar
• CraggGMLKingstonDGINewmanDJAnticancer Agents from Natural Products2nd edBoca RatonCRC Press2012
   Google Scholar
• TishlerRBSchiffPBGeardCRHallEJTaxol: a novel radiation sensitizerInt J Radiat Oncol Biol Phys19922236136171346533
   PubMed Web of Science ®Google Scholar
• AllumWHStenningSPBancewiczJClarkPILangleyRELong-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancerJ Clin Oncol200927305062506719770374
   PubMed Web of Science ®Google Scholar
• YamasakiMYasudaTYanoMMulticenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (dcf) compared with cisplatin and fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)Ann Oncol201728111612027687307
   PubMed Web of Science ®Google Scholar
• MarietteCDahanLMornexFSurgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901J Clin Oncol201432232416242224982463
   PubMed Web of Science ®Google Scholar
• HuangTCHsuCHLinCCTuYKSystematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancerJpn J Clin Oncol201545111023102826246479
   PubMed Web of Science ®Google Scholar
• DayFLLeongTNganSPhase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancerBr J Cancer2011104226527121157450
   PubMed Web of Science ®Google Scholar
• LiQQLiuMZHuYHLiuHHeZYLinHXDefinitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinomaDis Esophagus201023325325919732130
   PubMed Web of Science ®Google Scholar
• ZhangHZJinGFShenHBEpidemiologic differences in esophageal cancer between Asian and Western populationsChin J Cancer201231628128622507220
   PubMed Web of Science ®Google Scholar
• RuhstallerTWidmerLSchullerJCMulticenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)Ann Oncol20092091522152819465425
   PubMed Web of Science ®Google Scholar